By Charles S. Cleeland, Michael J. Fisch, Adrian J. Dunn
Melanoma Symptom technological know-how is the 1st interdisciplinary compilation of analysis at the mechanisms underlying the expression of cancer-related signs. It offers thoughts in scientific, animal and in vitro study, learn tools in mind imaging, and statistical-descriptive techniques to knowing the mechanistic foundation of symptom expression. This quantity additionally offers views from sufferers, executive and undefined. through gathering and synthesizing the constructing threads of recent ways to realizing cancer-related signs, the publication promotes a pioneering framework for merging behavioral and organic disciplines to elucidate mechanisms of symptom evolution, incorporating new applied sciences, checking out novel brokers for symptom keep watch over, and bettering sufferer functioning and caliber of lifestyles either in the course of and after melanoma remedy. With knowledgeable editorial workforce led by means of Charles S. Cleeland, an internationally-recognized chief in melanoma ache evaluation and remedy, this can be crucial analyzing for surgical, medical and clinical oncologists, educational researchers, and pharmaceutical businesses constructing new brokers to manage symptom expression
Preface; Foreword; half I. creation: 1. advent to melanoma Symptom technological know-how Charles S. Cleeland, Adrian J. Dunn and Michael J. Fisch; 2. gaining knowledge of the mechanisms underlying the indications of sufferers with melanoma Adrian J. Dunn; three. Cytokines, ailment habit: a version for melanoma signs Steven S. Zalcman, Randall T. Woodruff, Ruchika Mohla and Allan Siegal; half II. melanoma Symptom Mechanisms and versions: medical and uncomplicated technology: four. The scientific technological know-how of melanoma soreness evaluation and administration Russell ok. Portenoy and Victor T. Chang; five. discomfort: simple technology: 5a. Mechanisms of disease-related discomfort in melanoma: insights from the research of bone tumors Patrick W. Mantyh and Juan Miguel Jimenez Andrade; 5b. Neuropathic ache: easy technological know-how Patrick M. Dougherty and Haijun Zhang; 6. Cognitive disorder: is chemobrain genuine? Christina A. Meyers and Jeffrey S. Wefel; 7. Cognitive impairment: simple technology Perry N. Fuchs, Jessica A. Boyette-Davis and Adrian J. Dunn; eight. melancholy in melanoma: pathophysiology on the mind-body interface Andrew H. Miller, Michael A. Burke and Charles L. Raison; nine. Depressive disorder: simple technology: 9a. Animal types of depressed temper and disorder habit Adrian J. Dunn; 9b. From irritation to illness and melancholy: the cytokine connection Robert Dantzer and Keith W. Kelly; 10. Cancer-related fatigue: medical technology Xin Shelley Wang; eleven. constructing translational animal versions of cancer-related fatigue Mary W. Meagher; 12. melanoma anorexia/weight loss syndrome Aminah Jatoi and Nisha Lassi; thirteen. urge for food loss/cachexia: simple technology Tristin D. Brisbois-Clarkson, Wendy V. Wismer and Vickie E. Baracos; 14. Sleep and its problems: medical technological know-how Sofia Ancoli-Israel and Lianqi Liu; 15. Sleep and its problems Mark R. Opp and Luca Imeri; sixteen. Proteins and signs Bang-Ning Lee and James M. Reuben; 17. Genetic ways to treating and combating indicators in sufferers with melanoma Quiling Shi and Charles S. Cleeland; 18. useful imaging of signs T. Dorina Papageorgiou, Edward F. Jackson and Javier O. Valenzuela; 19. High-dose treatment and posttransplantation symptom burden: awesome a stability Sergio A. Giralt and Loretta A. Williams; half III. scientific views in Symptom administration and study: 20. selling symptom examine in cooperative teams Lynne I. Wagner and David Cella; 21. useful facets of symptom administration in sufferers with melanoma Richard T. Lee and Michael J. Fisch; half IV. Symptom dimension: 22. Symptom size by way of sufferer record Charles S. Cleeland and Tito R. Mendoza; 23. The economics of cancer-related indicators: valuing supportive care interventions Lesley-Ann Miller and Jane C. Weeks; 24. Longitudinal types for indicators Diane L. Fairclough; 25. Bayesian adaptive layout: a brand new method of try the effectiveness of symptom-reducing brokers utilizing patient-reported results Valen E. Johnson and Tito R. Mendoza; half V. executive and views: 26. selling melanoma symptom technology examine Ann O'Mara and Maria Sgambati; 27. constructing symptom administration medicinal drugs Joanna M. Brell and Lori M. Minasian; 28. Cancer-related indicators: matters for attention in drug and healing organic product label claims within the usa Jane A. Scott; 29. Symptom study: having a look forward Charles S. Cleeland, Adrian J. Dunn and Michael J. Fisch; Index
Read or Download Cancer Symptom Science : Measurement, Mechanisms, and Management PDF
Best oncology books
Views on melanoma Care is a different choice of insights from individuals, according to their particular services and adventure. It presents more than a few views on melanoma care which may encourage the readers and inspire prime quality care via an more suitable figuring out of the sufferers' wishes and the carers' talents.
A CONCISE but THOROUGH evaluate OF THE medicinal drugs AND techniques utilized in melanoma CARE--BACKED by means of THE AUTHORITY OF HARRISON'S Harrison's handbook of Oncology is a carry-anywhere consultant to the care of sufferers with melanoma. stronger via the most recent released effects, this necessary medical significant other good points a variety of tables and succinct, outline-style textual content that places vital details at your fingertips.
Perry’s The Chemotherapy resource publication, now in its 5th version, presents info at the collection of chemotherapeutic brokers, using blend chemotherapy, and the toxicity of person drugs. equipped by means of website, this can be the single e-book of its type to concentration strictly at the scientific perform of chemotherapy, and is intended to function a “one-stop store” for info on selection of chemotherapeutic brokers, remedy outlines, grading of unintended effects, and dose amendment.
- Cancer Control: Knowledge into Action: Diagnosis and Treatment (Who Guide for Effective Programmes)
- New Approaches in the Treatment of Cancer (Cancer Etiology, Diagnosis and Treatments)
- A Quick Guide to Cancer Epidemiology
- Atlas of Selective Sentinel Lymphadenectomy for Melanoma, Breast Cancer and Colon Cancer
- Practical Radiation Oncology Physics: A Companion to Gunderson & Tepper's Clinical Radiation Oncology, 1e
Extra resources for Cancer Symptom Science : Measurement, Mechanisms, and Management
Physiol Behav 60(1):277–282, 1996. 53. Anisman H, Kokkinidis L, Merali Z. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res 731(1–2):1–11, 1996. 66. Petitto JM, Lysle DT, Gariepy JL, Lewis MH. Association of genetic differences in social behavior and cellular immune responsiveness: effects of social experience. Brain Behav Immun 8(2):111–122, 1994. 54. Lapchak PA. A role for interleukin-2 in the regulation of striatal dopaminergic function.
Brain Res 933(2):98–108, 2002. 37. Glowa JR, Panlilio LV, Brenneman DE, Gozes I, Fridkin M, Hill JM. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res 570 (1–2):49–53, 1992. 38. , Cadet P, Tyring SK, Smith EM. Human immunodeficiency virus envelope glycoprotein 120 alters sleep and induces cytokine mRNA expression in rats [published errata appear in Am J Physiol 1996 Aug;271(2 Pt 2):section R following table of contents and 1996 Dec;271(6 Pt 3):section R following table of contents].
Another important issue is the severity of the pain at time of treatment. The investigator has to balance the need to control pain with the observation that analgesic effects are more easily detected if the patient has moderate to severe pain at baseline. The power to detect differences between study groups requires an adequate sample size. Large-scale studies in the treatment of cancer pain have been implemented in the last two decades by the National Cancer Institute cooperative study groups, and by the pharmaceutical industry (see Chapters 20 and 21).
Cancer Symptom Science : Measurement, Mechanisms, and Management by Charles S. Cleeland, Michael J. Fisch, Adrian J. Dunn